信达生物战略合作属正面惊喜,目标价111港元

摩根大通
Feb 11

一、合作背景与意义摩根大通发布研报指出,信达生物(01801)与礼来(LLY。US)达成了一项重要的战略合作协议,双方将共同在全球范围内开发聚焦于肿瘤和免疫学领域的新型生物制剂。这一合作被摩根大通视为正面惊喜,标志着信达生物在迈向全球性生物制药公司的过程中迈出了重要一步。此次合作不仅突显了信达生物研发平台的实力,也为其未来在国际市场的拓展奠定了坚实基础。二、信达生物的长期愿景在电话会议中,信达生物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10